Want to see JP:4536 full AI Analyst Report?
Santen Pharmaceutical Co (4536) Financial Statements
Santen Pharmaceutical Co Financial Overview
Santen Pharmaceutical Co's market cap is currently $574.81B. The company's EPS TTM is $92.83; its P/E ratio is 15.03; and it has a dividend yield of 2.24%. Santen Pharmaceutical Co is scheduled to report earnings on November 5, 2026, and the estimated EPS forecast is $31.24. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 300.00B | $ 291.62B | $ 301.96B | $ 279.04B | $ 266.26B |
| Gross Profit | $ 163.21B | $ 160.97B | $ 163.88B | $ 156.57B | $ 146.85B |
| Operating Income | $ 56.23B | $ 45.22B | $ 51.90B | $ 32.02B | $ 35.98B |
| EBITDA | $ 66.51B | $ 67.79B | $ 48.88B | $ 11.94B | $ 52.92B |
| Net Income | $ 36.26B | $ 37.37B | $ 26.64B | $ -14.95B | $ 27.22B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 93.00B | $ 80.88B | $ 94.58B | $ 57.90B | $ 83.01B |
| Total Assets | $ 409.28B | $ 423.03B | $ 435.70B | $ 421.18B | $ 459.98B |
| Total Debt | $ 33.95B | $ 34.75B | $ 35.16B | $ 35.96B | $ 22.00B |
| Net Debt | $ -59.04B | $ -46.12B | $ -59.42B | $ -21.94B | $ -61.02B |
| Total Liabilities | $ 124.10B | $ 127.02B | $ 130.33B | $ 127.88B | $ 123.13B |
| Stockholders' Equity | $ 286.24B | $ 296.99B | $ 306.05B | $ 293.98B | $ 337.49B |
| Cash Flow | |||||
| Free Cash Flow | $ 54.27B | $ 36.66B | $ 63.33B | $ 19.87B | $ 28.70B |
| Operating Cash Flow | $ 60.93B | $ 43.50B | $ 72.65B | $ 37.15B | $ 46.04B |
| Investing Cash Flow | $ -8.22B | $ -12.97B | $ -6.14B | $ -26.78B | $ -35.17B |
| Financing Cash Flow | $ -53.31B | $ -49.35B | $ -34.03B | $ -37.22B | $ 5.56B |
Currency in JPY